Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a poor prognosis.
• Despite initial treatment responses, acquired resistance leads to inevitable relapse in most patients.
• Current clinical classification lacks the granularity to support precision medicine strategies.

Purpose of the Study:

• To explore the molecular and immunological profiles of exceptional responders in SCLC.
• To identify potential biomarkers for predicting treatment response and guiding precision oncology.
• To discuss the role of novel therapeutic agents and multi-dimensional profiling in advancing SCLC treatment.

Main Methods:

• Review of molecular studies identifying SCLC subtypes (ASCL1, NEUROD1, POU2F3, YAP1).
• Analysis of clinical trial data (IMpower133, CASPIAN, ADRIATIC) for immunotherapy outcomes.
• Discussion of emerging biomarkers (PD-L1, TMB, DLL3, CD3, B7-H3) and novel agents (tarlatamab, ifinatamab deruxtecan).

Main Results:

• SCLC subtypes exhibit distinct biological traits and vulnerabilities.
• Immunotherapy has modestly improved survival but long-term responders remain a small subset (~12%).
• Novel agents show promise, but predictive markers are still needed.

Conclusions:

• Understanding exceptional responders is critical for advancing SCLC treatment.
• Comprehensive biomarker integration (tissue, blood, immune profiling) is essential.
• A multi-dimensional approach will improve patient selection for emerging precision therapies.